Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To evaluate the efficacy of MPDL3280A + bevacizumab and MPLD3280A monotherapy compared with sunitinib as measured by progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1) via an independent central radiologic review.
Critère d'inclusion
- ADVANCED RENAL CELL CARCINOMA,CARCINOM CU CELULE RENALE AVANSAT, NETRATAT